US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
JP2762522B2
(ja)
|
1989-03-06 |
1998-06-04 |
藤沢薬品工業株式会社 |
血管新生阻害剤
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
PT98990A
(pt)
|
1990-09-19 |
1992-08-31 |
American Home Prod |
Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
|
US5892112A
(en)
|
1990-11-21 |
1999-04-06 |
Glycomed Incorporated |
Process for preparing synthetic matrix metalloprotease inhibitors
|
US5120842A
(en)
|
1991-04-01 |
1992-06-09 |
American Home Products Corporation |
Silyl ethers of rapamycin
|
US5100883A
(en)
|
1991-04-08 |
1992-03-31 |
American Home Products Corporation |
Fluorinated esters of rapamycin
|
US5118678A
(en)
|
1991-04-17 |
1992-06-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
CA2102780C
(en)
|
1991-05-10 |
2007-01-09 |
Alfred P. Spada |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
|
US5118677A
(en)
|
1991-05-20 |
1992-06-02 |
American Home Products Corporation |
Amide esters of rapamycin
|
NZ243082A
(en)
|
1991-06-28 |
1995-02-24 |
Ici Plc |
4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
|
US5151413A
(en)
|
1991-11-06 |
1992-09-29 |
American Home Products Corporation |
Rapamycin acetals as immunosuppressant and antifungal agents
|
GB9125660D0
(en)
|
1991-12-03 |
1992-01-29 |
Smithkline Beecham Plc |
Novel compound
|
GB9300059D0
(en)
|
1992-01-20 |
1993-03-03 |
Zeneca Ltd |
Quinazoline derivatives
|
US5521184A
(en)
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
ZA935112B
(en)
|
1992-07-17 |
1994-02-08 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
ZA935111B
(en)
|
1992-07-17 |
1994-02-04 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
US5256790A
(en)
|
1992-08-13 |
1993-10-26 |
American Home Products Corporation |
27-hydroxyrapamycin and derivatives thereof
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
US5258389A
(en)
|
1992-11-09 |
1993-11-02 |
Merck & Co., Inc. |
O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
|
JP3560609B2
(ja)
|
1992-11-13 |
2004-09-02 |
イミュネックス・コーポレーション |
Elkリガンドと呼ばれる新規なサイトカイン
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
US5629327A
(en)
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
US5516658A
(en)
|
1993-08-20 |
1996-05-14 |
Immunex Corporation |
DNA encoding cytokines that bind the cell surface receptor hek
|
AU693475B2
(en)
|
1993-10-01 |
1998-07-02 |
Novartis Ag |
Pyrimidineamine derivatives and processes for the preparation thereof
|
US5656643A
(en)
|
1993-11-08 |
1997-08-12 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
JP4105761B2
(ja)
|
1993-11-19 |
2008-06-25 |
アボット・ラボラトリーズ |
ラパミシン(マクロライド)の半合成類似体免疫調節剤
|
SK78196A3
(en)
|
1993-12-17 |
1997-02-05 |
Sandoz Ag |
Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
WO1995024190A2
(en)
|
1994-03-07 |
1995-09-14 |
Sugen, Inc. |
Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
|
CA2189028A1
(en)
|
1994-04-15 |
1995-10-26 |
Gary M. Fox |
Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
|
EP0682027B1
(de)
|
1994-05-03 |
1997-10-15 |
Novartis AG |
Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
US6303769B1
(en)
|
1994-07-08 |
2001-10-16 |
Immunex Corporation |
Lerk-5 dna
|
US5919905A
(en)
|
1994-10-05 |
1999-07-06 |
Immunex Corporation |
Cytokine designated LERK-6
|
US6057124A
(en)
|
1995-01-27 |
2000-05-02 |
Amgen Inc. |
Nucleic acids encoding ligands for HEK4 receptors
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
EP0817775B1
(en)
|
1995-03-30 |
2001-09-12 |
Pfizer Inc. |
Quinazoline derivatives
|
ES2150113T3
(es)
|
1995-04-03 |
2000-11-16 |
Novartis Ag |
Derivados de pirazol y procedimientos para la preparacion de los mismos.
|
CA2218503C
(en)
|
1995-04-20 |
2001-07-24 |
Pfizer Inc. |
Arylsulfonyl hydroxamic acid derivatives
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
US5650415A
(en)
|
1995-06-07 |
1997-07-22 |
Sugen, Inc. |
Quinoline compounds
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
AU712193B2
(en)
|
1995-06-09 |
1999-10-28 |
Novartis Ag |
Rapamycin derivatives
|
US5624677A
(en)
|
1995-06-13 |
1997-04-29 |
Pentech Pharmaceuticals, Inc. |
Controlled release of drugs delivered by sublingual or buccal administration
|
CZ1598A3
(cs)
|
1995-07-06 |
1998-04-15 |
Novartis Ag |
Pyrrolopyrimidiny a způsoby jejich přípravy
|
AR004010A1
(es)
|
1995-10-11 |
1998-09-30 |
Glaxo Group Ltd |
Compuestos heterociclicos
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
PT780386E
(pt)
|
1995-12-20 |
2003-02-28 |
Hoffmann La Roche |
Inibidores de metaloprotease de matriz
|
EP0888349B1
(en)
|
1996-01-23 |
2002-05-22 |
Novartis AG |
Pyrrolopyrimidines and processes for their preparation
|
JP3406763B2
(ja)
|
1996-01-30 |
2003-05-12 |
東レ・ダウコーニング・シリコーン株式会社 |
シリコーンゴム組成物
|
GB9603097D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
DE19608588A1
(de)
|
1996-03-06 |
1997-09-11 |
Thomae Gmbh Dr K |
Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
DE19629652A1
(de)
|
1996-03-06 |
1998-01-29 |
Thomae Gmbh Dr K |
4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
US6051577A
(en)
|
1996-03-15 |
2000-04-18 |
Novartis Ag |
N-7-heterocyclyl pyrrolo[2,3-D]pyrimidines and the use thereof
|
DK0892789T4
(da)
|
1996-04-12 |
2010-04-06 |
Warner Lambert Co |
Irreversible inhibitorer af tyrosin kinaser
|
GB9607729D0
(en)
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
BR9709959A
(pt)
|
1996-06-24 |
2000-05-09 |
Pfizer |
Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
|
AU735648B2
(en)
|
1996-07-12 |
2001-07-12 |
Ariad Pharmaceuticals, Inc. |
Materials and method for treating or preventing pathogenic fungal infection
|
EP0818442A3
(en)
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
|
EA199900021A1
(ru)
|
1996-07-13 |
1999-08-26 |
Глаксо, Груп Лимитед |
Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
ID19609A
(id)
|
1996-07-13 |
1998-07-23 |
Glaxo Group Ltd |
Senyawa-senyawa heterosiklik
|
CN1225639A
(zh)
|
1996-07-18 |
1999-08-11 |
美国辉瑞有限公司 |
基于次膦酸酯的基质金属蛋白酶抑制剂
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
EP0920505B1
(en)
|
1996-08-16 |
2008-06-04 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
PL331895A1
(en)
|
1996-08-23 |
1999-08-16 |
Pfizer |
Arylosulphonylamino derivatives of hydroxamic acid
|
DK0938486T3
(da)
|
1996-08-23 |
2008-07-07 |
Novartis Ag |
Substituerede pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
US6251911B1
(en)
|
1996-10-02 |
2001-06-26 |
Novartis Ag |
Pyrimidine derivatives and processes for the preparation thereof
|
WO1998014449A1
(en)
|
1996-10-02 |
1998-04-09 |
Novartis Ag |
Fused pyrazole derivatives and processes for their preparation
|
EP0837063A1
(en)
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
GB9621757D0
(en)
|
1996-10-18 |
1996-12-11 |
Ciba Geigy Ag |
Phenyl-substituted bicyclic heterocyclyl derivatives and their use
|
US6077864A
(en)
|
1997-01-06 |
2000-06-20 |
Pfizer Inc. |
Cyclic sulfone derivatives
|
ID22799A
(id)
|
1997-02-03 |
1999-12-09 |
Pfizer Prod Inc |
Turunan-turunan asam arilsulfonilamino hidroksamat
|
WO1998033798A2
(en)
|
1997-02-05 |
1998-08-06 |
Warner Lambert Company |
Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
|
CA2279863A1
(en)
|
1997-02-07 |
1998-08-13 |
Pfizer Inc. |
N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
|
EP0960098A1
(en)
|
1997-02-11 |
1999-12-01 |
Pfizer Inc. |
Arylsulfonyl hydroxamic acid derivatives
|
CO4950519A1
(es)
|
1997-02-13 |
2000-09-01 |
Novartis Ag |
Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
|
US6150395A
(en)
|
1997-05-30 |
2000-11-21 |
The Regents Of The University Of California |
Indole-3-carbinol (I3C) derivatives and methods
|
US6329375B1
(en)
|
1997-08-05 |
2001-12-11 |
Sugen, Inc. |
Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
|
TR200000368T2
(tr)
|
1997-08-08 |
2000-07-21 |
Pfizer Products Inc. |
Ariloksiariarilsülfonilamino hidroksamik asit türevleri.
|
EP1025228A4
(en)
|
1997-10-21 |
2002-09-18 |
Human Genome Sciences Inc |
HUMAN PROTEIN TR11, TR11SV1 AND TR11SV2 SIMILAR TO THE TUMOR NECROSIS FACTOR RECEPTOR
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
GB9800569D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
IL137409A0
(en)
|
1998-02-09 |
2001-07-24 |
Genentech Inc |
Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
|
EP1066286B1
(en)
|
1998-03-04 |
2009-04-29 |
Bristol-Myers Squibb Company |
Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
|
PA8469401A1
(es)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
EP2020408B1
(en)
|
1998-05-29 |
2013-06-26 |
Sugen, Inc. |
Pyrrole substituted 2-indolinone protein kinase inhibitor
|
UA60365C2
(uk)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
|
CA2336848A1
(en)
|
1998-07-10 |
2000-01-20 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
CA2341409A1
(en)
|
1998-08-31 |
2000-03-09 |
Merck And Co., Inc. |
Novel angiogenesis inhibitors
|
US6114361A
(en)
|
1998-11-05 |
2000-09-05 |
Pfizer Inc. |
5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
|
ES2265929T3
(es)
|
1999-03-30 |
2007-03-01 |
Novartis Ag |
Derivados de ftalazina para el tratamiento de enfermedades inflamatorias.
|
GB9912961D0
(en)
|
1999-06-03 |
1999-08-04 |
Pfizer Ltd |
Metalloprotease inhibitors
|
US6521424B2
(en)
|
1999-06-07 |
2003-02-18 |
Immunex Corporation |
Recombinant expression of Tek antagonists
|
DE60027564T3
(de)
|
1999-06-07 |
2009-07-23 |
Immunex Corp., Thousand Oaks |
Tek-antagonisten
|
WO2001003720A2
(en)
|
1999-07-12 |
2001-01-18 |
Genentech, Inc. |
Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
|
IL147803A0
(en)
|
1999-08-24 |
2002-08-14 |
Ariad Gene Therapeutics Inc |
28-epirapalogs
|
IL149034A0
(en)
|
1999-11-05 |
2002-11-10 |
Astrazeneca Ab |
Quinazoline derivatives as vegf inhibitors
|
DK1233943T3
(da)
|
1999-11-24 |
2011-08-15 |
Sugen Inc |
Ioniserbare indolinon derivater og anvendelse deraf som PTK ligander
|
US6515004B1
(en)
|
1999-12-15 |
2003-02-04 |
Bristol-Myers Squibb Company |
N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
|
US6727225B2
(en)
|
1999-12-20 |
2004-04-27 |
Immunex Corporation |
TWEAK receptor
|
CA2406864A1
(en)
|
2000-02-24 |
2001-08-30 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
US7074408B2
(en)
|
2000-02-25 |
2006-07-11 |
Immunex Corporation |
Use of integrin antagonists to inhibit angiogenesis
|
US6630500B2
(en)
|
2000-08-25 |
2003-10-07 |
Cephalon, Inc. |
Selected fused pyrrolocarbazoles
|
PT1343782E
(pt)
|
2000-12-21 |
2009-06-29 |
Smithkline Beecham Corp |
Pirimidinoaminas como moduladores de angiogénese
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US7105682B2
(en)
|
2001-01-12 |
2006-09-12 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
US7102009B2
(en)
|
2001-01-12 |
2006-09-05 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
US20020147198A1
(en)
|
2001-01-12 |
2002-10-10 |
Guoqing Chen |
Substituted arylamine derivatives and methods of use
|
US7307088B2
(en)
|
2002-07-09 |
2007-12-11 |
Amgen Inc. |
Substituted anthranilic amide derivatives and methods of use
|
TWI329112B
(en)
|
2002-07-19 |
2010-08-21 |
Bristol Myers Squibb Co |
Novel inhibitors of kinases
|
WO2004107618A2
(en)
|
2003-05-23 |
2004-12-09 |
Wyeth |
Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof
|
MXPA06000117A
(es)
|
2003-07-08 |
2006-04-27 |
Novartis Ag |
Uso de rapamicina y derivados de rapamicina para el tratamiento de perdida osea.
|
EP1660126A1
(en)
|
2003-07-11 |
2006-05-31 |
Schering Corporation |
Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
|
EP1648900A4
(en)
|
2003-07-11 |
2010-02-10 |
Ariad Pharma Inc |
PHOSPHORUS MACROCYCLES
|
AR045134A1
(es)
|
2003-07-29 |
2005-10-19 |
Smithkline Beecham Plc |
Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
|
WO2005016894A1
(en)
|
2003-08-15 |
2005-02-24 |
Novartis Ag |
2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
|
EP1692318A4
(en)
|
2003-12-02 |
2008-04-02 |
Genzyme Corp |
COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
US20060002932A1
(en)
|
2004-06-04 |
2006-01-05 |
Duke University |
Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
|
KR100859891B1
(ko)
|
2004-08-26 |
2008-09-23 |
화이자 인코포레이티드 |
단백질 키나제 억제제로서 거울상이성질체적으로 순수한아미노헤테로아릴 화합물
|
CN101039952A
(zh)
|
2004-10-13 |
2007-09-19 |
惠氏公司 |
作为pi3k抑制剂的17-羟基渥曼青霉素类似物
|
JP5238936B2
(ja)
|
2005-03-25 |
2013-07-17 |
ジーアイティーアール,インク. |
Gitr結合分子およびその使用
|
PL2439273T3
(pl)
|
2005-05-09 |
2019-08-30 |
Ono Pharmaceutical Co., Ltd. |
Ludzkie przeciwciała monoklonalne przeciwko białku programowanej śmierci komórki 1(pd-1) oraz metody leczenia nowotworów z wykorzystaniem przeciwciał anty-pd-1 samodzielnie lub w połączeniu z innymi immunoterapeutykami
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
US20090012085A1
(en)
|
2005-09-20 |
2009-01-08 |
Charles Michael Baum |
Dosage forms and methods of treatment using a tyrosine kinase inhibitor
|
US20110212086A1
(en)
|
2006-01-19 |
2011-09-01 |
Genzyme Corporation |
GITR Antibodies For The Treatment of Cancer
|
ES2544082T3
(es)
|
2006-12-07 |
2015-08-27 |
F. Hoffmann-La Roche Ag |
Compuestos inhibidores de fosfoinosítido 3-quinasa y métodos de uso
|
JP5932217B2
(ja)
|
2007-07-12 |
2016-06-08 |
ジーアイティーアール, インコーポレイテッド |
Gitr結合分子を使用する併用療法
|
ES2537352T3
(es)
|
2007-09-12 |
2015-06-05 |
Genentech, Inc. |
Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapéuticos, y metodos para su uso
|
EP2214675B1
(en)
|
2007-10-25 |
2013-11-20 |
Genentech, Inc. |
Process for making thienopyrimidine compounds
|
KR20110044992A
(ko)
|
2008-07-02 |
2011-05-03 |
이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 |
TGF-β 길항제 다중-표적 결합 단백질
|
US8586023B2
(en)
|
2008-09-12 |
2013-11-19 |
Mie University |
Cell capable of expressing exogenous GITR ligand
|
US8709424B2
(en)
|
2009-09-03 |
2014-04-29 |
Merck Sharp & Dohme Corp. |
Anti-GITR antibodies
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
LT2519543T
(lt)
|
2009-12-29 |
2016-10-10 |
Emergent Product Development Seattle, Llc |
Heterodimerus rišantys baltymai ir jų panaudojimas
|
EP2937349B1
(en)
|
2011-03-23 |
2016-12-28 |
Amgen Inc. |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
TW201311689A
(zh)
*
|
2011-08-05 |
2013-03-16 |
必治妥美雅史谷比公司 |
作為因子xia抑制劑之新穎巨環化合物
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
JP6399660B2
(ja)
|
2012-04-10 |
2018-10-03 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
癌治療用組成物および方法
|
WO2014113584A1
(en)
|
2013-01-16 |
2014-07-24 |
Rhode Island Hospital |
Compositions and methods for the prevention and treatment of osteolysis and osteoporosis
|
JP6473133B2
(ja)
|
2013-03-15 |
2019-02-20 |
アラクセス ファーマ エルエルシー |
Krasg12cの共有結合性阻害剤
|
WO2014143659A1
(en)
|
2013-03-15 |
2014-09-18 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the gtpase k-ras g12c
|
WO2014176488A1
(en)
|
2013-04-26 |
2014-10-30 |
Indiana University Research & Technology Corporation |
Hydroxyindole carboxylic acid based inhibitors for oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (shp2)
|
SG11201602662YA
(en)
|
2013-10-10 |
2016-05-30 |
Araxes Pharma Llc |
Inhibitors of kras g12c
|
EP3094627B1
(en)
|
2014-01-17 |
2018-08-22 |
Novartis AG |
1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
EP3094629B1
(en)
|
2014-01-17 |
2018-08-22 |
Novartis AG |
1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
|
EP3197870B1
(en)
|
2014-09-25 |
2020-08-19 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
AU2016245864C1
(en)
|
2015-04-10 |
2021-09-09 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
CA2982360A1
(en)
|
2015-04-15 |
2016-10-20 |
Liansheng Li |
Fused-tricyclic inhibitors of kras and methods of use thereof
|
US20180121597A1
(en)
|
2015-05-22 |
2018-05-03 |
Allosta Pharmaceuticals |
Methods to Prepare and Employ Binding Site Models for Modulation of Phosphatase Activity and Selectivity Determination
|
US10532977B2
(en)
|
2015-06-01 |
2020-01-14 |
Indiana University Research And Technology Corporation |
Small molecule inhibitors of protein tyrosine phosphatases and uses thereof
|
ES2805232T3
(es)
|
2015-06-19 |
2021-02-11 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de SHP2
|
EP3310779B1
(en)
|
2015-06-19 |
2019-05-08 |
Novartis AG |
Compounds and compositions for inhibiting the activity of shp2
|
JP6878316B2
(ja)
|
2015-06-19 |
2021-05-26 |
ノバルティス アーゲー |
Shp2の活性を阻害するための化合物および組成物
|
EP3325447A1
(en)
|
2015-07-22 |
2018-05-30 |
Araxes Pharma LLC |
Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins
|
EP3356353A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
US10689356B2
(en)
|
2015-09-28 |
2020-06-23 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
US10875842B2
(en)
|
2015-09-28 |
2020-12-29 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
US10975071B2
(en)
|
2015-09-28 |
2021-04-13 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017058792A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017078499A2
(ko)
|
2015-11-06 |
2017-05-11 |
경북대학교 산학협력단 |
단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
|
WO2017079723A1
(en)
|
2015-11-07 |
2017-05-11 |
Board Of Regents, The University Of Texas System |
Targeting proteins for degradation
|
MX2018005967A
(es)
|
2015-11-16 |
2018-08-29 |
Araxes Pharma Llc |
Compuestos de quinazolina 2-sustituida que comprenden un grupo heterociclico sustituido y metodos de uso de los mismos.
|
US9932288B2
(en)
|
2015-12-09 |
2018-04-03 |
West Virginia University |
Chemical compound for inhibition of SHP2 function and for use as an anti-cancer agent
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
WO2017156397A1
(en)
|
2016-03-11 |
2017-09-14 |
Board Of Regents, The University Of Texas Sysytem |
Heterocyclic inhibitors of ptpn11
|
US10822312B2
(en)
|
2016-03-30 |
2020-11-03 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
JP7039489B2
(ja)
|
2016-05-18 |
2022-03-22 |
ミラティ セラピューティクス, インコーポレイテッド |
Kras g12c阻害剤
|
JP7044375B2
(ja)
|
2016-05-31 |
2022-03-30 |
ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
Ptpn11の複素環式阻害剤
|
CN112250670B
(zh)
|
2016-06-07 |
2021-06-08 |
北京加科思新药研发有限公司 |
可用作shp2抑制剂的新型杂环衍生物
|
PL3468972T3
(pl)
|
2016-06-14 |
2020-11-16 |
Novartis Ag |
Związki i kompozycje do hamowania aktywności shp2
|
IL264186B1
(en)
|
2016-07-12 |
2024-04-01 |
Revolution Medicines Inc |
2,5-dimutomers of 3-methylpyrazines and 2,5,6-dimutomers of 3-methylpyrazines as allosteric SHP2 inhibitors
|
US11529347B2
(en)
|
2016-09-22 |
2022-12-20 |
Relay Therapeutics, Inc. |
SHP2 phosphatase inhibitors and methods of use thereof
|
WO2018064510A1
(en)
|
2016-09-29 |
2018-04-05 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
CN110312711A
(zh)
|
2016-10-07 |
2019-10-08 |
亚瑞克西斯制药公司 |
作为ras抑制剂的杂环化合物及其使用方法
|
WO2018081091A1
(en)
|
2016-10-24 |
2018-05-03 |
Relay Therapeutics, Inc. |
Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
|
CN110291084A
(zh)
|
2016-12-15 |
2019-09-27 |
加利福尼亚大学董事会 |
用于治疗癌症的组合物和方法
|
UA124474C2
(uk)
|
2016-12-22 |
2021-09-22 |
Емджен Інк. |
БЕНЗІЗОТІАЗОЛЬНІ, ІЗОТІАЗОЛО[3,4-b]ПІРИДИНОВІ, ХІНАЗОЛІНОВІ, ФТАЛАЗИНОВІ, ПІРИДО[2,3-d]ПІРИДАЗИНОВІ Й ПІРИДО[2,3-d]ПІРИМІДИНОВІ ПОХІДНІ ЯК ІНГІБІТОРИ G12C KRAS ДЛЯ ЛІКУВАННЯ РАКУ ЛЕГЕНІ, РАКУ ПІДШЛУНКОВОЇ ЗАЛОЗИ АБО КОЛОРЕКТАЛЬНОГО РАКУ
|
US10988766B2
(en)
|
2017-01-06 |
2021-04-27 |
Oregon Health & Science University |
Compositions and methods used in diagnosing and treating colorectal cancer
|
KR102571130B1
(ko)
|
2017-01-10 |
2023-08-28 |
노파르티스 아게 |
Alk 저해제 및 shp2 저해제를 포함하는 약제학적 조합
|
JP7240319B2
(ja)
|
2017-01-23 |
2023-03-15 |
レヴォリューション・メディスンズ,インコーポレイテッド |
アロステリックshp2阻害剤としての二環式化合物
|
SG11201906412SA
(en)
|
2017-01-23 |
2019-08-27 |
Revolution Medicines Inc |
Pyridine compounds as allosteric shp2 inhibitors
|
WO2018140598A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused n-heterocyclic compounds and methods of use thereof
|
US11358959B2
(en)
|
2017-01-26 |
2022-06-14 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
US11059819B2
(en)
|
2017-01-26 |
2021-07-13 |
Janssen Biotech, Inc. |
Fused hetero-hetero bicyclic compounds and methods of use thereof
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
WO2018140513A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
JOP20190186A1
(ar)
|
2017-02-02 |
2019-08-01 |
Astellas Pharma Inc |
مركب كينازولين
|
WO2018160731A1
(en)
|
2017-02-28 |
2018-09-07 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
SG11201908820VA
(en)
|
2017-03-23 |
2019-10-30 |
Jacobio Pharmaceuticals Co Ltd |
Novel heterocyclic derivatives useful as shp2 inhibitors
|
AU2018263886C1
(en)
|
2017-05-02 |
2022-12-22 |
Revolution Medicines, Inc. |
Rapamycin analogs as mTOR inhibitors
|
AR111776A1
(es)
|
2017-05-11 |
2019-08-21 |
Astrazeneca Ab |
Heteroarilos inhibidores de las proteínas ras mutantes de g12c
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
CN110869358A
(zh)
|
2017-05-25 |
2020-03-06 |
亚瑞克西斯制药公司 |
Kras的共价抑制剂
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
TW201906832A
(zh)
|
2017-05-25 |
2019-02-16 |
美商亞瑞克西斯製藥公司 |
用於癌症治療之化合物及其使用方法
|
EP3630770A1
(en)
|
2017-05-26 |
2020-04-08 |
Relay Therapeutics, Inc. |
Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
|
KR20200051684A
(ko)
|
2017-09-07 |
2020-05-13 |
레볼루션 메디슨즈, 인크. |
암 치료를 위한 shp2 억제제 조성물 및 방법
|
EP3679040B1
(en)
|
2017-09-08 |
2022-08-03 |
Amgen Inc. |
Inhibitors of kras g12c and methods of using the same
|
CN111201223B
(zh)
|
2017-09-11 |
2024-07-09 |
克鲁松制药公司 |
SHP2的八氢环戊二烯并[c]吡咯别构抑制剂
|
ES2944547T3
(es)
|
2017-11-15 |
2023-06-22 |
Mirati Therapeutics Inc |
Inhibidores de KRas G12C
|
TW201938561A
(zh)
|
2017-12-08 |
2019-10-01 |
瑞典商阿斯特捷利康公司 |
化學化合物
|
WO2019152454A1
(en)
|
2018-01-30 |
2019-08-08 |
Research Development Foundation |
Shp2 inhibitors and methods of use thereof
|
CN108113848A
(zh)
|
2018-01-31 |
2018-06-05 |
力迈德医疗(广州)有限公司 |
上肢及头部康复训练机器人
|
TW201942115A
(zh)
|
2018-02-01 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
|
TW201942116A
(zh)
|
2018-02-09 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌劑之四氫喹唑啉衍生物
|
EP3753941B1
(en)
|
2018-02-13 |
2024-05-01 |
Shanghai Blueray Biopharma Co., Ltd. |
Pyrimidine-fused cyclic compound, preparation method therefor and application thereof
|
US11044675B2
(en)
|
2018-02-13 |
2021-06-22 |
Idac Holdings, Inc. |
Methods, apparatuses and systems for adaptive uplink power control in a wireless network
|
WO2019165073A1
(en)
|
2018-02-21 |
2019-08-29 |
Relay Therapeutics, Inc. |
Shp2 phosphatase inhibitors and methods of use thereof
|
CN111902415A
(zh)
|
2018-03-02 |
2020-11-06 |
大冢制药株式会社 |
药学化合物
|
CA3094690A1
(en)
|
2018-03-21 |
2019-09-26 |
Relay Therapeutics, Inc. |
Shp2 phosphatase inhibitors and methods of use thereof
|
EP3768680A1
(en)
|
2018-03-21 |
2021-01-27 |
Relay Therapeutics, Inc. |
Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof
|
JP7265275B2
(ja)
|
2018-03-21 |
2023-04-26 |
スージョウ プーヘー バイオファーマ カンパニー リミテッド |
Shp2阻害剤およびその使用
|
IL278335B1
(en)
|
2018-05-01 |
2024-05-01 |
Revolution Medicines Inc |
C26-linked rapamycin analogs as MTOR inhibitors
|
ES2945560T3
(es)
|
2018-05-01 |
2023-07-04 |
Revolution Medicines Inc |
Análogos de rapamicina unidos en C40, C28 y C-32 como inhibidores de mTOR
|
EP3787627A4
(en)
|
2018-05-02 |
2021-12-01 |
Navire Pharma, Inc. |
SUBSTITUTED HETEROCYCLIC INHIBITORS FOR PTPN11
|
WO2019213526A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
EP3788038B1
(en)
|
2018-05-04 |
2023-10-11 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
WO2019217307A1
(en)
|
2018-05-07 |
2019-11-14 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
TW202012415A
(zh)
|
2018-05-08 |
2020-04-01 |
瑞典商阿斯特捷利康公司 |
化學化合物
|
AU2019265822B2
(en)
|
2018-05-10 |
2024-07-18 |
Amgen Inc. |
KRAS G12C inhibitors for the treatment of cancer
|
AU2019278998B2
(en)
|
2018-06-01 |
2023-11-09 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
US20210230300A1
(en)
|
2018-06-04 |
2021-07-29 |
Bayer Aktiengesellschaft |
Inhibitors of shp2
|
MA52780A
(fr)
|
2018-06-11 |
2021-04-14 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
JP7369719B2
(ja)
|
2018-06-12 |
2023-10-26 |
アムジエン・インコーポレーテツド |
KRas G12C阻害剤及びそれを使用する方法
|
MX2021000795A
(es)
|
2018-07-24 |
2021-04-12 |
Taiho Pharmaceutical Co Ltd |
Compuestos heterociclicos para inhibir la actividad de shp2.
|
WO2020028706A1
(en)
|
2018-08-01 |
2020-02-06 |
Araxes Pharma Llc |
Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
|
WO2020033286A1
(en)
|
2018-08-06 |
2020-02-13 |
Purdue Research Foundation |
Novel sesquiterpenoid analogs
|
CA3109181A1
(en)
|
2018-08-10 |
2020-02-13 |
Navire Pharma, Inc. |
6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer
|
US11760744B2
(en)
|
2018-08-16 |
2023-09-19 |
Genentech, Inc. |
Fused ring compounds
|
US20210230170A1
(en)
|
2018-08-31 |
2021-07-29 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
EP3853234A1
(en)
|
2018-09-18 |
2021-07-28 |
Nikang Therapeutics, Inc. |
Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
|
CN112839935A
(zh)
|
2018-09-26 |
2021-05-25 |
北京加科思新药研发有限公司 |
可用作shp2抑制剂的新型杂环衍生物
|
IL305106A
(en)
|
2018-09-29 |
2023-10-01 |
Novartis Ag |
A process for producing a compound to inhibit the activity of SHP2
|
CN112867718A
(zh)
|
2018-09-29 |
2021-05-28 |
诺华股份有限公司 |
用于抑制shp2活性的化合物和组合物的制造
|
WO2020072656A1
(en)
|
2018-10-03 |
2020-04-09 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
CN111295384B
(zh)
|
2018-10-10 |
2022-08-12 |
江苏豪森药业集团有限公司 |
双环类衍生物抑制剂、其制备方法和应用
|
TW202028183A
(zh)
|
2018-10-10 |
2020-08-01 |
大陸商江蘇豪森藥業集團有限公司 |
含氮雜芳類衍生物調節劑、其製備方法和應用
|
CN114341124A
(zh)
|
2018-10-17 |
2022-04-12 |
Array生物制药公司 |
蛋白质酪氨酸磷酸酶抑制剂
|
CN117143079A
(zh)
|
2018-11-06 |
2023-12-01 |
上海奕拓医药科技有限责任公司 |
一种螺芳环化合物及其应用
|
WO2020094104A1
(zh)
|
2018-11-07 |
2020-05-14 |
如东凌达生物医药科技有限公司 |
一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
|
MX2021005700A
(es)
|
2018-11-19 |
2021-07-07 |
Amgen Inc |
Inhibidores de kras g12c y metodos de uso de los mismos.
|
CN109574871B
(zh)
|
2018-11-23 |
2022-01-04 |
上海交通大学 |
一种乙酰氨基偶氮苯类衍生物及其制备与应用
|
WO2020104635A1
(en)
|
2018-11-23 |
2020-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of shp2 inhibitors for the treatment of insulin resistance
|
WO2020108590A1
(zh)
|
2018-11-30 |
2020-06-04 |
上海拓界生物医药科技有限公司 |
嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
|
WO2020132597A1
(en)
|
2018-12-21 |
2020-06-25 |
Revolution Medicines, Inc. |
Compounds that participate in cooperative binding and uses thereof
|
EP3908283A4
(en)
|
2019-01-10 |
2022-10-12 |
Mirati Therapeutics, Inc. |
KRAS G12C INHIBITORS
|
WO2020156243A1
(zh)
|
2019-01-31 |
2020-08-06 |
贝达药业股份有限公司 |
Shp2抑制剂及其应用
|
WO2020156242A1
(zh)
|
2019-01-31 |
2020-08-06 |
贝达药业股份有限公司 |
Shp2抑制剂及其应用
|
KR20210126652A
(ko)
|
2019-02-12 |
2021-10-20 |
노파르티스 아게 |
Tno155 및 pd-1 억제제를 포함하는 약제학적 조합물
|
BR112021015632A2
(pt)
|
2019-02-12 |
2021-10-05 |
Novartis Ag |
Combinação farmacêutica que compreende tno155 e ribociclibe
|
US20220152026A1
(en)
|
2019-02-12 |
2022-05-19 |
Novartis Ag |
Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
|
CN111647000B
(zh)
|
2019-03-04 |
2021-10-12 |
勤浩医药(苏州)有限公司 |
吡嗪类衍生物及其在抑制shp2中的应用
|
AU2020232026A1
(en)
|
2019-03-07 |
2021-09-02 |
Merck Patent Gmbh |
Carboxamide-pyrimidine derivatives as shp2 antagonists
|
KR20210146389A
(ko)
|
2019-04-02 |
2021-12-03 |
어레이 바이오파마 인크. |
단백질 티로신 포스파타제 억제제
|
CA3127475A1
(en)
|
2019-04-08 |
2020-10-15 |
Merck Patent Gmbh |
Pyrimidinone derivatives as shp2 antagonists
|
CN112047937B
(zh)
|
2019-06-06 |
2023-04-07 |
劲方医药科技(上海)有限公司 |
四氢吡啶并[3,4-d]嘧啶-2(1H)-酮类化合物,其制法与医药上的用途
|
WO2020249079A1
(zh)
|
2019-06-14 |
2020-12-17 |
北京盛诺基医药科技股份有限公司 |
一种shp2磷酸酶变构抑制剂
|
CN112110918B
(zh)
|
2019-06-21 |
2023-08-22 |
劲方医药科技(上海)有限公司 |
螺环取代的嘧啶并环类化合物,其制法与医药上的用途
|
JP2022538548A
(ja)
|
2019-06-28 |
2022-09-05 |
トゥオチエ バイオテック (シャンハイ) カンパニー リミテッド |
ピリミジン5員環窒素複素環式誘導体、その調製方法およびその薬学的使用
|
CN111704611B
(zh)
|
2019-07-25 |
2022-01-14 |
上海凌达生物医药有限公司 |
一类芳基螺环类shp2抑制剂化合物、制备方法和用途
|
CN114195804A
(zh)
|
2019-07-30 |
2022-03-18 |
上海凌达生物医药有限公司 |
一类哌啶稠环类化合物、制备方法和用途
|
CN112300173B
(zh)
|
2019-07-30 |
2021-10-01 |
上海凌达生物医药有限公司 |
一类含氮多环类化合物、制备方法和用途
|
CN112300194B
(zh)
|
2019-07-30 |
2022-01-14 |
上海凌达生物医药有限公司 |
一类稠环吡啶酮类化合物、制备方法和用途
|
CN112300160A
(zh)
|
2019-08-01 |
2021-02-02 |
上海奕拓医药科技有限责任公司 |
一种螺芳环化合物、其制备及应用
|
EP3772513A1
(en)
|
2019-08-09 |
2021-02-10 |
C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening |
Shp2 inhibitors
|
CN112390818B
(zh)
|
2019-08-12 |
2023-08-22 |
劲方医药科技(上海)有限公司 |
取代的杂芳环并二氢嘧啶酮衍生物,其制法与医药上的用途
|
CN112390788A
(zh)
|
2019-08-13 |
2021-02-23 |
苏州闻天医药科技有限公司 |
一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途
|
GB201911928D0
(en)
|
2019-08-20 |
2019-10-02 |
Otsuka Pharma Co Ltd |
Pharmaceutical compounds
|
WO2021043077A1
(zh)
|
2019-09-06 |
2021-03-11 |
四川科伦博泰生物医药股份有限公司 |
一种取代吡嗪化合物、其制备方法和用途
|
US20230010886A1
(en)
|
2019-09-23 |
2023-01-12 |
Suzhou Puhe BioPharma Co., Ltd. |
Shp2 inhibitors and uses thereof
|
BR112022005349A2
(pt)
|
2019-09-24 |
2022-06-14 |
Relay Therapeutics Inc |
Inibidores de shp2 fosfatase e métodos de produção e uso dos mesmos
|
CN112724145A
(zh)
|
2019-10-14 |
2021-04-30 |
杭州雷索药业有限公司 |
用于抑制shp2活性的吡嗪衍生物
|
CN112225734B
(zh)
|
2019-10-25 |
2021-12-07 |
南京瑞捷医药科技有限公司 |
Kras g12c抑制剂及其用途
|
WO2021081752A1
(zh)
|
2019-10-29 |
2021-05-06 |
烟台杰瑞石油装备技术有限公司 |
一种整体式动力端结构的五缸柱塞泵
|
CN112778284B
(zh)
|
2019-11-01 |
2022-04-05 |
四川海思科制药有限公司 |
一种嘧啶并环衍生物及其在医药上的应用
|
JP2022553858A
(ja)
*
|
2019-11-04 |
2022-12-26 |
レボリューション メディシンズ インコーポレイテッド |
Ras阻害剤
|
CR20220240A
(es)
|
2019-11-04 |
2022-08-03 |
Revolution Medicines Inc |
Inhibidores de ras
|
MX2022005360A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
TW202120488A
(zh)
|
2019-11-08 |
2021-06-01 |
大陸商南京聖和藥業股份有限公司 |
作為shp2抑制劑的化合物及其應用
|
US20230034584A1
(en)
|
2019-12-04 |
2023-02-02 |
Bayer Aktiengesellschaft |
Inhibitors of shp2
|
CN112920183B
(zh)
|
2019-12-06 |
2024-07-19 |
南京圣和药业股份有限公司 |
作为kras-g12c抑制剂的化合物及其应用
|
CN113024544B
(zh)
|
2019-12-09 |
2024-07-02 |
武汉誉祥医药科技有限公司 |
一种含氰基并杂环化合物及其用途
|
CN114829362A
(zh)
|
2019-12-10 |
2022-07-29 |
成都倍特药业股份有限公司 |
一种可用作shp2抑制剂的含氮杂原子的六元并五元芳环衍生物
|
WO2021119525A1
(en)
|
2019-12-11 |
2021-06-17 |
Tiaki Therapeutics Inc. |
Shp1 and shp2 inhibitors and their methods of use
|
WO2021126816A1
(en)
|
2019-12-16 |
2021-06-24 |
Amgen Inc. |
Dosing regimen of a kras g12c inhibitor
|
US20230083431A1
(en)
|
2019-12-18 |
2023-03-16 |
Merck Sharp & Dohme Llc |
Macrocyclic peptides as potent inhibitors of k-ras g12d mutant
|
WO2021120045A1
(en)
|
2019-12-18 |
2021-06-24 |
InventisBio Co., Ltd. |
Heterocyclic compounds, preparation methods and uses thereof
|
CN113004269A
(zh)
|
2019-12-19 |
2021-06-22 |
首药控股(北京)有限公司 |
Kras-G12C抑制剂杂环化合物
|
CN114349750A
(zh)
|
2019-12-19 |
2022-04-15 |
北京加科思新药研发有限公司 |
Kras突变蛋白抑制剂
|
WO2021121397A1
(zh)
|
2019-12-19 |
2021-06-24 |
首药控股(北京)股份有限公司 |
取代的炔基杂环化合物
|
WO2021121371A1
(zh)
|
2019-12-19 |
2021-06-24 |
贝达药业股份有限公司 |
Kras g12c抑制剂及其在医药上的应用
|
WO2021127404A1
(en)
|
2019-12-20 |
2021-06-24 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
WO2021120890A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Pyrazolyl derivatives useful as anti-cancer agents
|
CN113024508A
(zh)
|
2019-12-25 |
2021-06-25 |
天津医科大学 |
一类含氮杂环衍生物及其制法和用途
|
CA3162106A1
(en)
|
2019-12-27 |
2021-07-01 |
Yuli Xie |
Spiro ring-containing quinazoline compound
|
CN113045565A
(zh)
|
2019-12-27 |
2021-06-29 |
微境生物医药科技(上海)有限公司 |
新型K-Ras G12C抑制剂
|
CN112094269B
(zh)
|
2020-01-01 |
2021-12-07 |
上海凌达生物医药有限公司 |
一类饱和六元环并杂环类化合物、制备方法和用途
|
WO2021139678A1
(zh)
|
2020-01-07 |
2021-07-15 |
广州百霆医药科技有限公司 |
吡啶并嘧啶类kras g12c突变蛋白抑制剂
|
TWI770760B
(zh)
|
2020-01-08 |
2022-07-11 |
大陸商蘇州亞盛藥業有限公司 |
螺環四氫喹唑啉
|
EP4087843A1
(en)
|
2020-01-10 |
2022-11-16 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
CN115175908B
(zh)
|
2020-01-13 |
2024-07-23 |
苏州泽璟生物制药股份有限公司 |
芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
|
WO2021143680A1
(zh)
|
2020-01-16 |
2021-07-22 |
浙江海正药业股份有限公司 |
杂芳基类衍生物及其制备方法和用途
|
WO2021143823A1
(zh)
|
2020-01-16 |
2021-07-22 |
浙江海正药业股份有限公司 |
吡啶或嘧啶类衍生物及其制备方法和用途
|
CN113135910A
(zh)
|
2020-01-19 |
2021-07-20 |
北京诺诚健华医药科技有限公司 |
嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用
|
CN113135924B
(zh)
|
2020-01-19 |
2024-04-26 |
广东东阳光药业股份有限公司 |
嘧啶衍生物及其在药物中的应用
|
WO2021150613A1
(en)
|
2020-01-20 |
2021-07-29 |
Incyte Corporation |
Spiro compounds as inhibitors of kras
|
CN115003668A
(zh)
|
2020-01-21 |
2022-09-02 |
南京明德新药研发有限公司 |
作为kras抑制剂的大环类化合物
|
WO2021147879A1
(zh)
|
2020-01-21 |
2021-07-29 |
贝达药业股份有限公司 |
Shp2抑制剂及其应用
|
WO2021148010A1
(zh)
|
2020-01-22 |
2021-07-29 |
南京明德新药研发有限公司 |
吡唑并杂芳环类化合物及其应用
|
WO2021149817A1
(en)
|
2020-01-24 |
2021-07-29 |
Taiho Pharmaceutical Co., Ltd. |
Enhancement of anti-tumor activity of SHP2 inhibitor pyrimidinone in combination with novel cancer medicines in cancers
|
GB202001344D0
(en)
|
2020-01-31 |
2020-03-18 |
Redx Pharma Plc |
Ras Inhibitors
|
CN112159405B
(zh)
|
2020-02-04 |
2021-09-14 |
广州必贝特医药技术有限公司 |
吡啶并嘧啶酮类化合物及其应用
|
KR20210100557A
(ko)
|
2020-02-06 |
2021-08-17 |
웰마커바이오 주식회사 |
Kras 돌연변이와 관련된 암의 예방 또는 치료용 약학 조성물
|
CN113248521B
(zh)
|
2020-02-11 |
2023-07-18 |
上海和誉生物医药科技有限公司 |
一种k-ras g12c抑制剂及其制备方法和应用
|
US20230099858A1
(en)
|
2020-02-20 |
2023-03-30 |
Beta Pharma, Inc. |
Pyridopyrimidine derivatives as kras inhibitors
|
CN111265529B
(zh)
|
2020-02-22 |
2021-07-23 |
南京大学 |
蛋白酪氨酸磷酸酶shp2抑制剂在制备治疗银屑病药物中的应用
|
JP7462985B2
(ja)
|
2020-02-24 |
2024-04-08 |
上海▲テツ▼▲ギョウ▼生物科技有限公司 |
芳香族化合物および抗腫瘍薬物の調製におけるその使用
|
WO2021169990A1
(zh)
|
2020-02-24 |
2021-09-02 |
泰励生物科技(上海)有限公司 |
用于癌症治疗的kras抑制剂
|
US20210292330A1
(en)
|
2020-02-28 |
2021-09-23 |
Erasca, Inc. |
Pyrrolidine-fused heterocycles
|
CN114901663B
(zh)
|
2020-03-02 |
2024-07-02 |
上海喆邺生物科技有限公司 |
一类芳香杂环类化合物及其在药物中的应用
|
IT202000004849A1
(it)
|
2020-03-06 |
2021-09-06 |
Univ Degli Studi Di Roma “Tor Vergata” |
Peptidi e loro usi
|
EP4105211A4
(en)
|
2020-03-12 |
2023-09-06 |
D3 Bio(Wuxi) Co., Ltd. |
PYRIMIDOHETEROCYCLIC COMPOUNDS AND THEIR APPLICATION
|
WO2021185233A1
(en)
|
2020-03-17 |
2021-09-23 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras mutant protein inhibitors
|
JP2023519815A
(ja)
|
2020-03-25 |
2023-05-15 |
ウィゲン・バイオメディシン・テクノロジー・(シャンハイ)・カンパニー・リミテッド |
スピロ環含有キナゾリン化合物
|
DE102020204310B3
(de)
|
2020-04-02 |
2021-04-01 |
Thyssenkrupp Steel Europe Ag |
Stahl-Fahrzeugrad
|
CN113493440A
(zh)
|
2020-04-03 |
2021-10-12 |
上海翰森生物医药科技有限公司 |
含氮杂芳类衍生物的盐及其晶型
|
CN112142735B
(zh)
|
2020-04-09 |
2021-09-17 |
上海凌达生物医药有限公司 |
一类稠和氰基吡啶类化合物、制备方法和用途
|
PE20230825A1
(es)
|
2020-04-16 |
2023-05-19 |
Incyte Corp |
Inhibidores de kras triciclicos fusionados
|
CN113527299B
(zh)
|
2020-04-18 |
2023-12-29 |
上海凌达生物医药有限公司 |
一类含氮稠环类化合物、制备方法和用途
|
CN113527293B
(zh)
|
2020-04-20 |
2023-09-08 |
苏州璞正医药有限公司 |
Kras g12c突变蛋白抑制剂及其药物组合物、制备方法和用途
|
WO2021216770A1
(en)
|
2020-04-22 |
2021-10-28 |
Accutar Biotechnology Inc. |
Substituted tetrahydroquinazoline compounds as kras inhibitors
|
WO2021217019A1
(en)
|
2020-04-23 |
2021-10-28 |
The Regents Of The University Of California |
Ras inhibitors and uses thereof
|
US20230174518A1
(en)
|
2020-04-24 |
2023-06-08 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
US20230181536A1
(en)
|
2020-04-24 |
2023-06-15 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
WO2021218939A1
(zh)
|
2020-04-28 |
2021-11-04 |
贝达药业股份有限公司 |
稠环化合物及其在医药上的应用
|
CN114605401B
(zh)
|
2020-04-28 |
2023-08-22 |
江南大学 |
一类含氧五元杂环化合物、合成方法、药物组合物及用途
|
CN115151532B
(zh)
|
2020-04-29 |
2023-06-06 |
北京泰德制药股份有限公司 |
喹喔啉二酮衍生物作为kras g12c突变蛋白的不可逆抑制剂
|
EP4144732A4
(en)
|
2020-04-29 |
2024-05-01 |
Shanghai Ringene BioPharma Co., Ltd. |
BENZOTHIAZOLYL BIARYL COMPOUND, PREPARATION METHOD AND USE THEREOF
|
WO2021218755A1
(zh)
|
2020-04-30 |
2021-11-04 |
贝达药业股份有限公司 |
Shp2抑制剂及其组合物和应用
|
TW202144349A
(zh)
|
2020-04-30 |
2021-12-01 |
大陸商上海科州藥物研發有限公司 |
作為kras抑制劑的雜環化合物的製備及其應用方法
|
US11739102B2
(en)
|
2020-05-13 |
2023-08-29 |
Incyte Corporation |
Fused pyrimidine compounds as KRAS inhibitors
|
CN113666923A
(zh)
|
2020-05-15 |
2021-11-19 |
苏州泽璟生物制药股份有限公司 |
烷氧基烷基取代杂环基类抑制剂及其制备方法和应用
|
CN113683616A
(zh)
|
2020-05-18 |
2021-11-23 |
广州百霆医药科技有限公司 |
Kras g12c突变蛋白抑制剂
|
TWI799871B
(zh)
|
2020-05-27 |
2023-04-21 |
大陸商勁方醫藥科技(上海)有限公司 |
三環并環類化合物,其製法與醫藥上的用途
|
CN116234806A
(zh)
|
2020-06-02 |
2023-06-06 |
勃林格殷格翰国际有限公司 |
用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物
|
CA3182507A1
(en)
|
2020-06-04 |
2021-12-09 |
Bo Shan |
Inhibitors of kras g12c protein and uses thereof
|
WO2021248083A1
(en)
|
2020-06-05 |
2021-12-09 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
US20230026856A1
(en)
|
2020-06-05 |
2023-01-26 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
WO2021248090A1
(en)
|
2020-06-05 |
2021-12-09 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
WO2021248079A1
(en)
|
2020-06-05 |
2021-12-09 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
WO2021248082A1
(en)
|
2020-06-05 |
2021-12-09 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
CN113754653A
(zh)
|
2020-06-05 |
2021-12-07 |
明慧医药(上海)有限公司 |
一种kras g12c抑制剂化合物及其用途
|
CN113754683A
(zh)
|
2020-06-05 |
2021-12-07 |
上海奕拓医药科技有限责任公司 |
同位素取代的螺芳环化合物及其应用
|
JP2023528595A
(ja)
|
2020-06-05 |
2023-07-05 |
ペプシコ・インク |
飲料を冷却するためのチラー
|
WO2021252339A1
(en)
|
2020-06-08 |
2021-12-16 |
Accutar Biotechnology, Inc. |
Substituted purine-2,6-dione compounds as kras inhibitors
|
CN115515946A
(zh)
|
2020-06-11 |
2022-12-23 |
贝达药业股份有限公司 |
Shp2抑制剂及其组合物和应用
|
CN115734966A
(zh)
|
2020-06-12 |
2023-03-03 |
石药集团中奇制药技术(石家庄)有限公司 |
杂环化合物及其用途
|
WO2021257828A1
(en)
|
2020-06-18 |
2021-12-23 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
JP2023530838A
(ja)
|
2020-06-22 |
2023-07-20 |
スーチュアン・コールン-バイオテック・バイオファーマシューティカル・カンパニー・リミテッド |
置換されたピラジン化合物、当該化合物を含む医薬組成物、及びその使用
|
CN113896710A
(zh)
|
2020-06-22 |
2022-01-07 |
山东轩竹医药科技有限公司 |
Shp2抑制剂及其用途
|
WO2021259331A1
(zh)
|
2020-06-24 |
2021-12-30 |
南京明德新药研发有限公司 |
八元含n杂环类化合物
|
EP4175947A4
(en)
|
2020-06-30 |
2024-07-03 |
Inventisbio Co Ltd |
QUINAZOLINE COMPOUNDS, PRODUCTION PROCESSES AND USES THEREOF
|
CN113880827A
(zh)
|
2020-07-03 |
2022-01-04 |
苏州闻天医药科技有限公司 |
一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途
|
CN112823796A
(zh)
|
2020-07-08 |
2021-05-21 |
南京大学 |
蛋白酪氨酸磷酸酶shp2抑制剂在制备治疗骨关节炎药物中的应用
|
WO2022007869A1
(zh)
|
2020-07-10 |
2022-01-13 |
浙江海正药业股份有限公司 |
吡啶或嘧啶类衍生物及其制备方法和用途
|
CN113929676A
(zh)
|
2020-07-14 |
2022-01-14 |
浙江海正药业股份有限公司 |
吡啶并杂环类衍生物及其制备方法和用途
|
WO2022015375A1
(en)
|
2020-07-16 |
2022-01-20 |
Mirati Therapeutics, Inc. |
Kras g12d inhibitors
|
US20230339882A1
(en)
|
2020-07-24 |
2023-10-26 |
Betta Pharmaceuticals Co., Ltd. |
Shp2 inhibitor and composition and application thereof
|
CN113980014B
(zh)
|
2020-07-27 |
2023-05-12 |
江苏恒瑞医药股份有限公司 |
氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
|
CN113980032B
(zh)
|
2020-07-27 |
2023-06-16 |
江苏恒瑞医药股份有限公司 |
稠合四环类衍生物、其制备方法及其在医药上的应用
|
US20220036968A1
(en)
|
2020-07-30 |
2022-02-03 |
Frontier Medicines Corporation |
Processing biophysical screening data and identifying and characterizing protein sites for drug discovery
|
CN115052870B
(zh)
|
2020-08-02 |
2024-02-20 |
上海喆邺生物科技有限公司 |
一种芳香类化合物及其在抗肿瘤药物中的应用
|
US20230339976A1
(en)
|
2020-08-04 |
2023-10-26 |
Mirati Therapeutics, Inc. |
Kras g12d inhibitors
|
CN114057744A
(zh)
|
2020-08-05 |
2022-02-18 |
百济神州(北京)生物科技有限公司 |
制备kras g12c抑制剂咪唑并三嗪和吡咯并嘧啶衍生物的方法
|
CN114057743A
(zh)
|
2020-08-05 |
2022-02-18 |
百济神州(北京)生物科技有限公司 |
制备kras g12c抑制剂咪唑并三嗪和吡咯并嘧啶衍生物的方法
|
US20230322788A1
(en)
|
2020-08-05 |
2023-10-12 |
Beigene, Ltd. |
Imidazotriazine and pyrrolopyrimidine derivatives as kras g12c inhibitors
|
WO2022033430A1
(zh)
|
2020-08-10 |
2022-02-17 |
深圳微芯生物科技股份有限公司 |
一种杂三环类化合物及其制备方法和应用
|
WO2022040469A1
(en)
|
2020-08-19 |
2022-02-24 |
The Trustees Of The Stevens Institute Of Technology |
Spiro compounds as kras inhibitors
|
WO2022037560A1
(zh)
|
2020-08-21 |
2022-02-24 |
广东东阳光药业有限公司 |
嘧啶酮衍生物及其在药物中的应用
|
WO2022042331A1
(zh)
|
2020-08-25 |
2022-03-03 |
四川科伦博泰生物医药股份有限公司 |
杂环化合物及其制备方法和用途
|
GB202013321D0
(en)
|
2020-08-26 |
2020-10-07 |
Xeros Ltd |
Treatment process
|
EP4204412A1
(en)
|
2020-08-26 |
2023-07-05 |
InventisBio Co., Ltd. |
Heteroaryl compounds, preparation methods and uses thereof
|
US11999752B2
(en)
|
2020-08-28 |
2024-06-04 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of KRAS
|
KR20230081726A
(ko)
*
|
2020-09-03 |
2023-06-07 |
레볼루션 메디슨즈, 인크. |
Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도
|
CN114163457A
(zh)
|
2020-09-11 |
2022-03-11 |
赣江新区博瑞创新医药有限公司 |
嘧啶并五元氮杂环化合物及其用途
|
CA3190944A1
(en)
|
2020-09-11 |
2022-03-17 |
Mirati Therapeutics, Inc. |
Crystalline forms of a kras g12c inhibitor
|
WO2022052895A1
(zh)
|
2020-09-11 |
2022-03-17 |
南京明德新药研发有限公司 |
氮杂环丁烷取代化合物的晶型
|
JP2023541916A
(ja)
|
2020-09-15 |
2023-10-04 |
レボリューション メディシンズ インコーポレイテッド |
がんの治療における、ras阻害剤としてのインドール誘導体
|
CN114195788A
(zh)
|
2020-09-17 |
2022-03-18 |
苏州闻天医药科技有限公司 |
一类四环化合物及其用途
|
WO2022061251A1
(en)
|
2020-09-18 |
2022-03-24 |
Plexxikon Inc. |
Compounds and methods for kras modulation and indications therefor
|
US20230357277A1
(en)
|
2020-09-22 |
2023-11-09 |
Mirati Therapeutics, Inc. |
Kras g12d inhibitors
|
WO2022063190A1
(zh)
|
2020-09-23 |
2022-03-31 |
南京明德新药研发有限公司 |
吡嗪硫联苯基类化合物及其应用
|
MX2023003338A
(es)
|
2020-09-23 |
2023-06-14 |
Erasca Inc |
Piridonas y pirimidonas tricíclicas.
|
CN116390728B
(zh)
|
2020-09-27 |
2024-03-29 |
微境生物医药科技(上海)有限公司 |
喹唑啉衍生物及其制备方法和用途
|
WO2022072783A1
(en)
|
2020-10-02 |
2022-04-07 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of kras
|
EP4225383A1
(en)
|
2020-10-08 |
2023-08-16 |
Kumquat Biosciences Inc. |
Modulators of cell proliferation and uses thereof
|
WO2022078414A1
(en)
|
2020-10-14 |
2022-04-21 |
Ranok Therapeutics (Hangzhou) Co. Ltd. |
Methods and compositions for targeted protein degradation
|
WO2022081655A1
(en)
|
2020-10-14 |
2022-04-21 |
Accutar Biotechnology, Inc. |
Substituted dihydropyranopyrimidine compounds as kras inhibitors
|
TW202233629A
(zh)
|
2020-10-20 |
2022-09-01 |
美商安進公司 |
雜環螺環化合物及使用方法
|
WO2022083616A1
(zh)
|
2020-10-21 |
2022-04-28 |
贝达药业股份有限公司 |
一种喹唑啉化合物及其药物组合物
|
TW202231273A
(zh)
|
2020-10-21 |
2022-08-16 |
美商博奥阿迪斯有限公司 |
作為ras抑制劑的化合物及其用途
|
WO2022087371A1
(en)
|
2020-10-22 |
2022-04-28 |
Spectrum Pharmaceuticals, Inc. |
Novel bicyclic compounds
|
WO2022087375A1
(en)
|
2020-10-22 |
2022-04-28 |
Spectrum Pharmaceuticals, Inc. |
Novel heterocyclic compounds
|
CN112402385B
(zh)
|
2020-11-30 |
2022-04-01 |
北京华氏开元医药科技有限公司 |
4-羟甲基-1h-吲哚类化合物药物制剂及其制备方法
|
CN113999226B
(zh)
|
2020-12-22 |
2023-01-06 |
上海科州药物研发有限公司 |
作为kras抑制剂的杂环化合物的制备及其应用方法
|
CN112920131A
(zh)
|
2021-03-03 |
2021-06-08 |
天津医科大学 |
一类1,2,4-三氮唑衍生物及其制法和用途
|
CN113248449B
(zh)
|
2021-05-06 |
2022-09-23 |
中国药科大学 |
一种含甲脒的芳基螺环类化合物及其制备方法与应用
|
CN113429405A
(zh)
|
2021-06-10 |
2021-09-24 |
都创(上海)医药开发有限公司 |
Mrtx849化合物的晶型及其制备方法和用途
|
CN113527294A
(zh)
|
2021-08-25 |
2021-10-22 |
都创(上海)医药开发有限公司 |
Mrtx849化合物的晶型及其制备方法和用途
|
CN114057776A
(zh)
|
2021-10-31 |
2022-02-18 |
南京碳硅人工智能生物医药技术研究院有限公司 |
一种具有抗癌活性的嘧啶并哌啶衍生物的新合成方法
|
CN114213417B
(zh)
|
2021-11-16 |
2023-08-22 |
郑州大学 |
吡唑并六元氮杂环类化合物及其合成方法和应用
|